Anssi Auvinen, Teuvo L J Tammela, Tuomas Mirtti, Hans Lilja, Teemu Tolonen, Anu Kenttämies, Irina Rinta-Kiikka, Terho Lehtimäki, Kari Natunen, Jaakko Nevalainen, Jani Raitanen, Johanna Ronkainen, Theodorus van der Kwast, Jarno Riikonen, Anssi Pétas, Mika Matikainen, Kimmo Taari, Tuomas Kilpeläinen, Antti S Rannikko
IMPORTANCE: Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important. OBJECTIVE: To describe rates of low-grade (grade group 1) and high-grade (grade groups 2-5) prostate cancer identified among men invited to participate in a prostate cancer screening protocol consisting of a PSA test, a 4-kallikrein panel, and a magnetic resonance imaging (MRI) scan. DESIGN, SETTING, AND PARTICIPANTS: The ProScreen trial is a clinical trial conducted in Helsinki and Tampere, Finland, that randomized 61 193 men aged 50 through 63 years who were free of prostate cancer in a 1:3 ratio to either be invited or not be invited to undergo screening for prostate cancer between February 2018 and July 2020...
April 6, 2024: JAMA